Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 [Yahoo! Finance]
Biomea Fusion, Inc. (BMEA)
Company Research
Source: Yahoo! Finance
developed assets and says it is funded through Q1 2027 to reach planned milestones without needing additional financing. The lead program, icovamenib , is a potential first-in-class menin inhibitor targeting beta-cell restoration; 12-week data showed a 1.2% HbA1c reduction and increased C-peptide that persisted off drug, supporting a possible non-chronic "one-and-done" approach, while liver enzyme elevations have been manageable at the 100 mg dose after an earlier FDA hold. Biomea's oral GLP-1–related obesity program is in Phase I and aims to improve pharmacokinetics and patient persistence; encouraging animal weight-loss data were presented and human Phase I readouts are expected by the end of Q2 as a near-term value driver. Interested in Biomea Fusion, Inc.? Here are five stocks we like better. Are (More) Big Gains Ahead for This Small Cap Biotech Stock? Biomea Fusion (NASDAQ:BMEA) outlined its focus on diabetes and obesity at the Citizens Life Sciences Conference, highlig
Show less
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026GlobeNewswire
- Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion to Participate at Upcoming Investor ConferencesGlobeNewswire
BMEA
Earnings
- 11/4/25 - Miss
BMEA
Sec Filings
- 2/25/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/12/26 - Form SCHEDULE
- BMEA's page on the SEC website